117 related articles for article (PubMed ID: 36268941)
1. GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
Rugo HS; Cortes J; Barrios CH; Cabrera P; Xu B; Huang CS; Kim SB; Melisko M; Nanda R; Pieńkowski T; Rapoport BL; Schwab R
Future Oncol; 2022 Oct; ():. PubMed ID: 36268941
[TBL] [Abstract][Full Text] [Related]
2. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.
Huang CS; Yu AL; Tseng LM; Chow LWC; Hou MF; Hurvitz SA; Schwab RB; L Murray J; Chang HK; Chang HT; Chen SC; Kim SB; Hung JT; Ueng SH; Lee SH; Chen CC; Rugo HS
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718986
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer.
Hung JT; Chen IJ; Ueng SH; Huang CS; Chen SC; Chen MY; Lin YC; Lin CY; Campbell MJ; Rugo HS; Yu AL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732348
[TBL] [Abstract][Full Text] [Related]
4. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
5. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
[TBL] [Abstract][Full Text] [Related]
6. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X; Wang SS; Huang H; Cai L; Zhao L; Peng RJ; Lin Y; Tang J; Zeng J; Zhang LH; Ke YL; Wang XM; Liu XM; Chen QJ; Zhang AQ; Xu F; Bi XW; Huang JJ; Li JB; Pang DM; Xue C; Shi YX; He ZY; Lin HX; An X; Xia W; Cao Y; Guo Y; Su YH; Hua X; Wang XY; Hong RX; Jiang KK; Song CG; Huang ZZ; Shi W; Zhong YY; Yuan ZY;
JAMA; 2021 Jan; 325(1):50-58. PubMed ID: 33300950
[TBL] [Abstract][Full Text] [Related]
7. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Nanda R; Liu MC; Yau C; Shatsky R; Pusztai L; Wallace A; Chien AJ; Forero-Torres A; Ellis E; Han H; Clark A; Albain K; Boughey JC; Jaskowiak NT; Elias A; Isaacs C; Kemmer K; Helsten T; Majure M; Stringer-Reasor E; Parker C; Lee MC; Haddad T; Cohen RN; Asare S; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Schwab R; Symmans WF; van 't Veer L; Yee D; DeMichele A; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Berry DA; Esserman LJ
JAMA Oncol; 2020 May; 6(5):676-684. PubMed ID: 32053137
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
[TBL] [Abstract][Full Text] [Related]
9. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
[TBL] [Abstract][Full Text] [Related]
10. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
11. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Bell R; Brown J; Parmar M; Toi M; Suter T; Steger GG; Pivot X; Mackey J; Jackisch C; Dent R; Hall P; Xu N; Morales L; Provencher L; Hegg R; Vanlemmens L; Kirsch A; Schneeweiss A; Masuda N; Overkamp F; Cameron D
Ann Oncol; 2017 Apr; 28(4):754-760. PubMed ID: 27993816
[TBL] [Abstract][Full Text] [Related]
12. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
13. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Mayer EL; Dueck AC; Martin M; Rubovszky G; Burstein HJ; Bellet-Ezquerra M; Miller KD; Zdenkowski N; Winer EP; Pfeiler G; Goetz M; Ruiz-Borrego M; Anderson D; Nowecki Z; Loibl S; Moulder S; Ring A; Fitzal F; Traina T; Chan A; Rugo HS; Lemieux J; Henao F; Lyss A; Antolin Novoa S; Wolff AC; Vetter M; Egle D; Morris PG; Mamounas EP; Gil-Gil MJ; Prat A; Fohler H; Metzger Filho O; Schwarz M; DuFrane C; Fumagalli D; Theall KP; Lu DR; Bartlett CH; Koehler M; Fesl C; DeMichele A; Gnant M
Lancet Oncol; 2021 Feb; 22(2):212-222. PubMed ID: 33460574
[TBL] [Abstract][Full Text] [Related]
15. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
16. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
Sharma P; Stecklein SR; Yoder R; Staley JM; Schwensen K; O'Dea A; Nye L; Satelli D; Crane G; Madan R; O'Neil MF; Wagner J; Larson KE; Balanoff C; Kilgore L; Phadnis MA; Godwin AK; Salgado R; Khan QJ; O'Shaughnessy J
JAMA Oncol; 2024 Feb; 10(2):227-235. PubMed ID: 37991778
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
[TBL] [Abstract][Full Text] [Related]
20. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
O'Sullivan CC; Ballman KV; McCall L; Kommalapati A; Zemla T; Weiss A; Mitchell M; Blinder V; Tung NM; Irvin WJ; Lee M; Goetz MP; Symmans WF; Borges VF; Krop I; Carey LA; Partridge AH
Future Oncol; 2021 Dec; 17(34):4665-4676. PubMed ID: 34636255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
